The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned class of heart medicines called CETP inhibitors.
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned class of heart medicines called CETP inhibitors.
